Corning secures US$104M funding from BARDA for glass packaging manufacturing

US – US-based technology company Corning is to receive US$103.8 million of funding from  BARDA for planned domestic glass tubing and vial manufacturing.

Based in Corning, New York, Corning specializes in specialty glass, ceramics and related materials and technologies.

The company’s solutions are designed primarily for industrial and scientific applications.

Corning will use the funding to expand its capacity for manufacturing advanced, high-quality pharmaceutical glass tubing and vials, helping the healthcare industry rapidly scale manufacturing to address current and future public health challenges.

The company will continue to increase its pharmaceutical tubing manufacturing capacity in Vineland, New Jersey, and its vial production capacity in Durham, North Carolina.

BARDA’s funding is intended to support the healthcare industry in addressing present and future public health challenges, as well as bolster the domestic pharmaceutical supply chain by increasing manufacturing efficiency.

Corning Pharmaceutical Technologies Vice-President and General Manager Brendan Mosher said: “Corning’s pharmaceutical glass packaging has played a critical role in ensuring the safe and on-time delivery of critical medications.

“Our Valor Glass and Velocity Vials are some of the strongest, fastest to fill, and highest-quality pharmaceutical glass vials available.

“Our products play a critical role in helping to protect patients by improving glass quality, lowering the risk of contamination, and helping to accelerate the delivery of lifesaving treatments.”

The investment comes after BARDA committed to providing US$204 million of funding to Corning in June 2020.

The previous funding was intended to expand the company’s domestic capacity for manufacturing Corning Valor Glass vials to expedite the delivery of Covid-19 vaccines.

The expansion plans come at a time when the global pharmaceutical glass packaging market size is valued at US$3.79 billion and is expected to expand at a compound annual growth rate (CAGR) of 8.8% from 2022 to 2028.

Extensive utilization of generic injectable drugs, coupled with the high demand from the pharmaceutical industry, is anticipated to drive the market.

Glass poses a hindrance to atmospheric gases, such as carbon dioxide and oxygen, from entering the primary container, mitigating the risk of contamination of the drugs.

Glass packaging lowers the drug’s susceptibility to degradation, such as hydrolysis and oxidation.

In addition, it also helps in resisting the escape of volatile ingredients, thereby increasing drug stability.

Liked this article? Subscribe to our regular email newsletters with the latest news insights from Africa and the World’s packaging and printing industry. SUBSCRIBE HERE.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.